# Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

> **NCT03414892** · PHASE1 · COMPLETED · sponsor: **Yabao Pharmaceutical Group** · enrollment: 24 (actual)

## Conditions studied

- Hyperglycaemia (Diabetic)
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Globalagliatin Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03414892
- **Lead sponsor:** Yabao Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2019-01-04
- **Final completion:** 2019-12-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414892, "Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03414892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*